

# PROVIDER QUICK POINTS

## PROVIDER INFORMATION



February 27, 2019

### Pharmacy Benefit Exclusion for Ultomiris™ (ravulizumab-cwvz) IV Injection

Blue Cross and Blue Shield of Minnesota and Blue Plus (Blue Cross) is committed to providing subscribers with safe, quality, pharmacy care.

Ultomiris™ (ravulizumab-cwvz) IV injection is a new drug product approved by the Food and Drug Administration (FDA) for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Effective April 1, 2019, Ultomiris™ (ravulizumab-cwvz) will be excluded from pharmacy benefit coverage due to clinician-administered route of administration. Ultomiris™ (ravulizumab-cwvz) may be available for medical benefit coverage for subscribers who are eligible.

Drug Name
Ultomiris™ (ravulizumab-cwvz) IV injection

### Products Impacted

This notice applies to commercial lines of business **and** the following Minnesota Health Care Programs:

- Families and Children [*formerly known as* Prepaid Medical Assistance Program (PMAP)]
- MinnesotaCare (MNCare)
- Minnesota Senior Care Plus (MSC+)

### Questions?

If you have questions, please contact provider services at **(651) 662-5200** or **1-800-262-0820**.